vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $220.8M, roughly 1.5× UNIVERSAL TECHNICAL INSTITUTE INC). HAEMONETICS CORP runs the higher net margin — 13.2% vs 5.8%, a 7.4% gap on every dollar of revenue. On growth, UNIVERSAL TECHNICAL INSTITUTE INC posted the faster year-over-year revenue change (9.6% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-19.2M). Over the past eight quarters, UNIVERSAL TECHNICAL INSTITUTE INC's revenue compounded faster (9.5% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
HAE vs UTI — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $220.8M |
| Net Profit | $44.7M | $12.8M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | 7.1% |
| Net Margin | 13.2% | 5.8% |
| Revenue YoY | -2.7% | 9.6% |
| Net Profit YoY | 19.3% | -42.1% |
| EPS (diluted) | $0.95 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $220.8M | ||
| Q3 25 | $327.3M | $222.4M | ||
| Q2 25 | $321.4M | $204.3M | ||
| Q1 25 | $330.6M | $207.4M | ||
| Q4 24 | $348.5M | $201.4M | ||
| Q3 24 | $345.5M | $196.4M | ||
| Q2 24 | $336.2M | $177.5M | ||
| Q1 24 | — | $184.2M |
| Q4 25 | $44.7M | $12.8M | ||
| Q3 25 | $38.7M | $18.8M | ||
| Q2 25 | $34.0M | $10.7M | ||
| Q1 25 | $58.0M | $11.4M | ||
| Q4 24 | $37.5M | $22.2M | ||
| Q3 24 | $33.8M | $18.8M | ||
| Q2 24 | $38.4M | $5.0M | ||
| Q1 24 | — | $7.8M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | 7.1% | ||
| Q3 25 | 17.9% | 11.2% | ||
| Q2 25 | 16.8% | 6.9% | ||
| Q1 25 | 21.6% | 8.1% | ||
| Q4 24 | 16.9% | 13.6% | ||
| Q3 24 | 15.0% | 13.3% | ||
| Q2 24 | 11.8% | 4.2% | ||
| Q1 24 | — | 6.1% |
| Q4 25 | 13.2% | 5.8% | ||
| Q3 25 | 11.8% | 8.4% | ||
| Q2 25 | 10.6% | 5.2% | ||
| Q1 25 | 17.5% | 5.5% | ||
| Q4 24 | 10.8% | 11.0% | ||
| Q3 24 | 9.8% | 9.6% | ||
| Q2 24 | 11.4% | 2.8% | ||
| Q1 24 | — | 4.2% |
| Q4 25 | $0.95 | $0.23 | ||
| Q3 25 | $0.81 | $0.33 | ||
| Q2 25 | $0.70 | $0.19 | ||
| Q1 25 | $1.17 | $0.21 | ||
| Q4 24 | $0.74 | $0.40 | ||
| Q3 24 | $0.66 | $0.35 | ||
| Q2 24 | $0.74 | $0.09 | ||
| Q1 24 | — | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $162.8M |
| Total DebtLower is stronger | $1.2B | $101.4M |
| Stockholders' EquityBook value | $911.5M | $335.9M |
| Total Assets | $2.5B | $834.0M |
| Debt / EquityLower = less leverage | 1.34× | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $162.8M | ||
| Q3 25 | $296.4M | $169.1M | ||
| Q2 25 | $292.9M | $70.7M | ||
| Q1 25 | $306.8M | $96.0M | ||
| Q4 24 | $320.8M | $172.0M | ||
| Q3 24 | $299.3M | $161.9M | ||
| Q2 24 | $344.4M | $115.5M | ||
| Q1 24 | — | $116.1M |
| Q4 25 | $1.2B | $101.4M | ||
| Q3 25 | $1.2B | $87.1M | ||
| Q2 25 | $1.2B | $73.8M | ||
| Q1 25 | $1.2B | $94.4M | ||
| Q4 24 | — | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | — | $141.9M |
| Q4 25 | $911.5M | $335.9M | ||
| Q3 25 | $849.2M | $328.1M | ||
| Q2 25 | $882.3M | $306.8M | ||
| Q1 25 | $820.8M | $293.9M | ||
| Q4 24 | $906.9M | $280.0M | ||
| Q3 24 | $878.9M | $260.2M | ||
| Q2 24 | $905.4M | $239.4M | ||
| Q1 24 | — | $232.6M |
| Q4 25 | $2.5B | $834.0M | ||
| Q3 25 | $2.4B | $826.1M | ||
| Q2 25 | $2.5B | $740.8M | ||
| Q1 25 | $2.5B | $720.4M | ||
| Q4 24 | $2.5B | $753.8M | ||
| Q3 24 | $2.5B | $744.6M | ||
| Q2 24 | $2.5B | $706.0M | ||
| Q1 24 | — | $702.1M |
| Q4 25 | 1.34× | 0.30× | ||
| Q3 25 | 1.44× | 0.27× | ||
| Q2 25 | 1.39× | 0.24× | ||
| Q1 25 | 1.49× | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | — | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $3.1M |
| Free Cash FlowOCF − Capex | $87.2M | $-19.2M |
| FCF MarginFCF / Revenue | 25.7% | -8.7% |
| Capex IntensityCapex / Revenue | 1.9% | 10.1% |
| Cash ConversionOCF / Net Profit | 2.09× | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $3.1M | ||
| Q3 25 | $111.3M | $57.1M | ||
| Q2 25 | $17.4M | $18.1M | ||
| Q1 25 | $116.6M | $-789.0K | ||
| Q4 24 | $43.8M | $23.0M | ||
| Q3 24 | $48.8M | $67.5M | ||
| Q2 24 | $-27.4M | $10.0M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | $87.2M | $-19.2M | ||
| Q3 25 | $106.3M | $40.6M | ||
| Q2 25 | $13.6M | $6.8M | ||
| Q1 25 | $100.9M | $-11.7M | ||
| Q4 24 | $35.2M | $19.6M | ||
| Q3 24 | $39.4M | $60.0M | ||
| Q2 24 | $-33.1M | $3.0M | ||
| Q1 24 | — | $-8.4M |
| Q4 25 | 25.7% | -8.7% | ||
| Q3 25 | 32.5% | 18.3% | ||
| Q2 25 | 4.2% | 3.4% | ||
| Q1 25 | 30.5% | -5.7% | ||
| Q4 24 | 10.1% | 9.7% | ||
| Q3 24 | 11.4% | 30.6% | ||
| Q2 24 | -9.8% | 1.7% | ||
| Q1 24 | — | -4.6% |
| Q4 25 | 1.9% | 10.1% | ||
| Q3 25 | 1.5% | 7.4% | ||
| Q2 25 | 1.2% | 5.5% | ||
| Q1 25 | 4.7% | 5.3% | ||
| Q4 24 | 2.5% | 1.7% | ||
| Q3 24 | 2.7% | 3.8% | ||
| Q2 24 | 1.7% | 4.0% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | 2.09× | 0.24× | ||
| Q3 25 | 2.88× | 3.04× | ||
| Q2 25 | 0.51× | 1.69× | ||
| Q1 25 | 2.01× | -0.07× | ||
| Q4 24 | 1.17× | 1.04× | ||
| Q3 24 | 1.44× | 3.58× | ||
| Q2 24 | -0.71× | 2.01× | ||
| Q1 24 | — | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
